Big Pharma has been big busy this week. On Monday, French pharma leviathan Sanofi purchased San Francisco-based immunology specialist company Principia Biopharma for $3.68 billion. Not to be outdone, Johnson & Johnson, one of the companies working on a COVID-19 vaccine with federal grants, announced it will purchase Cambridge, Massachusetts-based Momenta Pharmaceuticals for $6.5 billion. 

In the Sanofi deal, Weil, Gotshal & Manges represented Sanofi, with the firm’s mergers and acquisitions chairman Michael Aiello and M&A partner Sachin Kohli leading the way. 

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]